Clinical trials: Castrate-resistant Prostate Cancer
Metastatic Castration Resistant Prostate Cancer
Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response
The primary aim is to show whether a reduction in tumor related mRNAs and a panel of selected miRNAS can be used to personalize enzalutamide therapy.
- Trial name
- ILUMINATE (NCT02471469)
- Testing
- Enzalutamide, 160mg, 40 mg soft capsules, once daily
- Where
- 3 sites in Netherlands
- Volunteers
- 40 people
- Sponsor
- Radboud University Medical Center
Metastatic Castration-resistant Prostate Cancer
Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion
The goal of this clinical trial is to test the anti-tumor activity of bortezomib in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC) with PTEN Deletion.
- Trial name
- BORXPTEN (NCT06029998)
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Utah
Castrate Resistant Prostate Cancer, Bone Metastases
Health-related Quality of Life, Psychological Distress and Fatigue in Metastatic CRPC Patients Treated With Radium-223
The aim of the current prospective multicenter study is to evaluate cancer-specific and bone metastases related HR-QoL, psychological distress and fatigue in mCRPC patients before, during and after treatment with radium-223 in…
- Trial name
- NCT04995614
- Testing
- Radium-223
- Where
- 11 sites in Netherlands
- Volunteers
- 122 people
- Sponsor
- Radboud University Medical Center
Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma
Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
This randomized phase II trial studies how well docetaxel and prednisone with or without vaccine therapy works in treating patients with hormone-resistant prostate cancer that has spread to other parts of the body.
- Conditions
- Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT01145508
- Testing
- Docetaxel, Laboratory Biomarker Analysis, Prednisone
- Where
- 14 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Hormone-refractory Prostate Cancer
Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy
This study is a phase I study of a cell based prostate cancer therapy, Autologous Lymphoid Effector Cells Specific Against Tumor-cells (ALECSAT).
- Trial name
- ALECSAT (NCT01422850)
- Testing
- ALECSAT
- Where
- Denmark
- Volunteers
- 21 people
- Sponsor
- CytoVac A/S
Prostate Cancer
Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC
Two-part, multi-center study design to establish a maximum tolerated dose (MTD) of ZD4054 in combination with docetaxel and to explore its safety, tolerability, pharmacokinetic (PK) profiles and clinical efficacy in patients with…
- Trial name
- NCT00314782
- Testing
- ZD4054 (Zibotentan), Docetaxel
- Where
- 9 sites in United States, Germany and 1 more
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)
Researchers in this study want to compare how well drug radium-223 dichloride (Xofigo) and androgen receptor pathway inhibitor (ARPI) therapy work in participants with prostate gland cancer which has spread to the bone and…
- Trial name
- RADIANT (NCT04597125)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), ARPI therapy
- Where
- 117 sites in Australia, Austria and 17 more
- Volunteers
- 654 people
- Sponsor
- Bayer
Metastatic Breast Cancer, Advanced Breast Cancer
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
This is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib.
- Conditions
- Metastatic Breast Cancer, Advanced Breast Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Renal Cell Cancer
- Trial name
- NCT00428220
- Testing
- sunitinib
- Where
- 113 sites in United States, Argentina and 15 more
- Volunteers
- 223 people
- Sponsor
- Pfizer
Prostate Cancer
Prospective CiRculating prOstate Cancer Predictors in HighEr Risk mCRPC studY
This study will develop a first-in-man CTC-based molecular taxonomy of CRPC in the context of novel AR-directed therapies, categorize different patterns of resistance in this disease setting, and describe their evolution over…
- Trial name
- PROPHECY (NCT02269982)
- Testing
- AR-v7 assays
- Where
- 5 sites in United States
- Volunteers
- 120 people
- Sponsor
- Duke University
Prostate Cancer
Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.
The goal of this clinical study is to determine the efficacy and safety of Seviteronel, a lyase-selective inhibitor of CYP17 and an androgen receptor antagonist, in patients with castration-resistant prostate cancer (CRPC) who…
- Trial name
- NCT02445976
- Testing
- Seviteronel: given orally once daily in 28-day cycles
- Where
- 21 sites in United States
- Volunteers
- 197 people
- Sponsor
- Innocrin Pharmaceutical
Prostate Cancer, Metastatic Prostate Cancer
MENCORE-2: Audio Recordings to Improve Decision-making in Advanced Prostate Cancer
This is a single-arm hybrid implementation trial of men with metastatic castrate-resistant prostate cancer (mCRPC) involving a patient-administered mobile app for consultation audio recordings.
- Conditions
- Prostate Cancer, Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
- Trial name
- NCT05127850
- Testing
- Consultation audio recording app
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- University of California, San Francisco
Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
This phase Ib trial studies the side effects and best dose of DS3201 when given together with and ipilimumab for the treatment of patients with prostate, urothelial, or renal cell cancer that has spread to other places in the…
- Conditions
- Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT04388852
- Testing
- Ipilimumab, Valemetostat
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
mCRPC, Male Urogenital Diseases
The Radium-select Study
Radium-223 is an established radionuclide therapy for patients with metastatic castration resistant prostate cancer (mCRPC) and symptomatic bone metastasis.
- Trial name
- NCT06659926
- Testing
- 68Ga-PSMA-PET/CT scan
- Where
- 5 sites in Netherlands
- Volunteers
- 60 people
- Sponsor
- The Netherlands Cancer Institute
Metastatic Castration-resistant Prostate Cancer, mCRPC
Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer
Ten to 20% of patients with prostate cancer (PC) experience progression in their disease, even after undergoing pharmaceutical or surgical castration, leading to metastatic CRPC (mCRPC).
- Trial name
- NCT06377683
- Testing
- 177Lu-Dansyl-PSMA radioligand therapy
- Where
- China
- Volunteers
- 8 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Hormone Refractory Prostate Cancer
PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC
This is a Phase II, open-label study in male patients with metastatic HRPC. Each cycle will be 21 days (3 weeks). Patients will receive the following drugs: Docetaxel 75 mg/m2 IV given over 1 hour on Day 1.
- Trial name
- NCT00313482
- Testing
- Sargramostim, Docetaxel, Prednisone
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Veeda Oncology
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer
This is phase I, open label, multicentre, dose-escalation study where both doses of talazoparib and pidnarulex will be escalated to define the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) for the combination.
- Trial name
- REPAIR (NCT05425862)
- Testing
- Pidnarulex, Talazoparib
- Where
- 5 sites in Australia
- Volunteers
- 4 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Solid Tumors, Non-small Cell Lung Cancer
Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)
The purpose of this study is to assess the efficacy and safety of navarixin (MK-7123) in combination with pembrolizumab (MK-3475) in adults with one of three types of solid tumors: Programmed Death-Ligand 1 (PD-L1) positive…
- Conditions
- Solid Tumors, Non-small Cell Lung Cancer, Castration Resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer
- Trial name
- NCT03473925
- Testing
- Navarixin, Pembrolizumab
- Where
- 14 sites in United States, Australia and 3 more
- Volunteers
- 107 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Castration-resistant Prostate Cancer
FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
This study is an open-label, multicenter study designed to investigate the efficacy, safety and tolerability of FPI-2265 (225Ac-PSMA-I\&T) in combination with Olaparib in participants with mCRPC.
- Trial name
- NCT06909825
- Testing
- FPI-2265, Olaparib
- Where
- 4 sites in Australia
- Volunteers
- 85 people
- Sponsor
- Fusion Pharmaceuticals Inc.
Prostate Cancer
A Study of Imatinib and Docetaxel in Prostate Cancer
The purpose of this study is to determine the effectiveness of two drugs, docetaxel and Gleevec®(also called imatinib), in prostate cancer that no longer responds to hormone therapy.
- Trial name
- NCT00251225
- Testing
- Gleevec, Docetaxel
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Leonard Appleman
Metastatic Castration-resistant Prostate Cancer
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.
- Trial name
- VECTRA-01 (NCT07611110)
- Testing
- Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]), Cabazitaxel, Abiraterone
- Where
- 151 sites in United States, Australia and 22 more
- Volunteers
- 670 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.